At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo- and Active Comparator-controlled, Crossover Trial to Examine the Effect of Multiple Doses of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subject
In Brief
A Phase 1 clinical trial evaluating CVL-865 High dose, Alprazolam 1mg XR, and 2 other interventions for Panic Disorder. Completed, enrolled 56 participants across 1 site.
Detailed Summary
The purpose of this study is to determine anxiolytic effect of multiple doses of CVL-865 using an experimental medicine model of carbon dioxide (CO2) inhalation in healthy volunteers.
Study Details
Timeline
Interventions
High dose CVL-865: Will be administered as 5mg BID for 2 days followed by 12.5mg BID for another 2 days during the Titration Phase. 25mg will be administered during the Maintenance Phase (3 days of BID and morning dose only on the 4th day)
Alprazolam 1mg XR will be administered for 8 days BID (morning dose only on 8th day)
Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day)
Low dose CVL-865, oral tablets. Will be administered as 2.5mg BID for 2 days followed by 5mg BID for another 2 days during the Titration Phase. 7.5mg BID will be administered during the Maintenance Phase (3 days of BID and morning dose only on 4th day)